SHORT-TERM EFFECT OF SELEXIPAG IN COMPARISON TO PROSTACYCLIN ANALOGUES IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STARTED ON DOUBLE-COMBINATION THERAPY WITH ERA AND PDE-5 INHIBITORS

TYPE: Abstract TOPIC: Pulmonary Vascular Disease PURPOSE: GRIPHON trial demonstrated that Selexipag reduces the risk of death or morbidity events in patients with pulmonary arterial hypertension (PAH). Anyway its efficacy comparison to prostacyclin analogues already on oral double-combination therapy endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE5-I) is unknown. We compare effects (S) vs subcutaneous Treprostinil (T) intravenous Epoprostenol (E) PAH initially started ERA PDE5-I. METHODS: enrolled double combination + PDE5-I starting S, T E. All were systematically assessed WHO-functional class (FC), six minute walk test (6MWT) right heart catheterization before treatment 3 months after reaching a stable dose drug. Baseline characteristics changes 6MWT haemodynamic parameters analyzed using Wilcoxon signed-rank compared between drugs Kruskal- Wallis test. RESULTS: 171 enrolled. Patients complete re- evaluation 61% 85% T, 79% E (see Table below). Legend: CI, cardiac index; mPAP, mean pressure; PVR, vascular resistance; RAP, atrial SvO2, mixed venous oxygen saturation. CONCLUSIONS: S was prescribed oldest least severe patients. youngest most led strongest improvement exercise capacity profile. has intermediate characteristics. CLINICAL IMPLICATIONS: Triple sequential should be different classes severity DISCLOSURE: Nothing declare. KEYWORD: prostanoid